Companies AIM ImmunoTech Inc.
AIM ImmunoTech (AIM): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me AIM ImmunoTech Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $1,089,725FY2024
- $822,983FY2025
CEO total pay was $822,983 in fiscal 2025, down from $1,089,725 in fiscal 2024.
FY2025: salary $716,667 · bonus $0 · stock awards $0 · option awards $0
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Thomas Equels | $716,667 | $0 | $0 | $0 | $0 | $0 | $106,316 | $822,983 |
| CEO & President | ||||||||
| Peter Rodino | 391,666 | 0 | 0 | 0 | 0 | 0 | 65,348 | 457,014 |
| COO, Exec. Director for Governmental Relations, General Counsel and Secretary | ||||||||
| Robert Dickey IV | 108,420 | 0 | 0 | 0 | 0 | 0 | 0 | 108,420 |
| CFO | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Thomas Equels | $822,983 | $1,089,725 | — | ↓ −266,742 |
| Peter Rodino | 457,014 | 521,349 | — | ↓ −64,335 |
| Robert Dickey IV | 108,420 | 49,549 | — | ↑ +58,871 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Compensation Committee's primary objectives are to attract and retain talented executives, tie annual and long-term cash and stock incentives to measurable performance objectives, and align executives' incentives with stockholder value creation. Compensation levels are set to be comparable with executives at similarly sized biotechnology companies at a similar stage of development.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Steven Hall & Partners, LLC |
| Clawback policy | true |
| Anti-hedging | false |
| Anti-pledging | false |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
No outstanding equity awards are on file for this fiscal year.
Director compensation
No director compensation table is on file for fiscal year 2025.
Board fee structure and ownership guideline
| Annual cash retainer | $90,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | — |
| Stock ownership guideline | — |
Peer group, and who names AIM ImmunoTech as a peer
Companies that benchmark against AIM
No companies currently name AIM as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | AIM ImmunoTech Inc. | 2025 | Thomas Equels | $716,667 | $0 | $0 | $0 | $822,983 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (5 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Thomas Equels. DEF 14A, filed 2026-09-30. Section “Executive Compensation”. As printed: 822,983. View filing ↗
- Section 01, Peter Rodino. DEF 14A, filed 2026-09-30. Section “Executive Compensation”. As printed: 457,014. View filing ↗
- Section 01, Robert Dickey IV. DEF 14A, filed 2026-09-30. Section “Executive Compensation”. As printed: 108,420. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- AIM ImmunoTech Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-09-30. CEO total compensation as printed in AIM ImmunoTech Inc.'s own proxy. As printed: 822,983. View filing ↗